# MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

> **NCT03230838** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 134 (actual)

## Conditions studied

- Complicated Urinary Tract Infection
- Pyelonephritis

## Interventions

- **DRUG:** Ceftolozane/Tazobactam
- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT03230838
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2020-12-03
- **Final completion:** 2020-12-03
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03230838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03230838, "MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03230838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*